NASDAQ PROK Transforming the Future of Chronic Kidney Disease Treatment Preserving Kidney Function in Patients at High Risk of Kidney Failure 44th Annual J.P. Morgan Healthcare Conference Bruce Culleton, MD Chief Executive Officer January 14, 2026 Copyright © 2026 ProKidney Corp. All rights reserved. Forward-looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. ProKidney's actual ...

44th Annual J.P. Morgan Healthcare Conference Emmanuel Ligner President and CEO January 14, 2026 Disclaimer Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this presentation are for ...

Business Overview - Agios is positioned for growth and aims for profitability with its existing commercial portfolio[3, 4] - The company has a strong foundation in hematology and aspires to become a sustainable rare disease company[5] - Agios estimates a total global market size of over $10 billion by 2030 for its current pipeline indications[11] Product Pipeline and Approvals - AQVESME (mitapivat) is now approved in the U S for anemia in adults with alpha- or beta-thalassemia, addressing approximately 4,000 addressable patients at launch[7, 17, 23] - AQVESME has a potential to deliver $1 billion in global peak-year-sales across PKD and thalassemia indications[24] - Pyrukynd is approved in the U S , EU, and UK for Pyruvate Kinase Deficiency[7] Clinical Development - In Sickle Cell Disease, 40.6% of patients achieved Hemoglobin response (≥1 g/dL) in the mitapivat trial[37] - Phase 1 tebapivat data demonstrates a 1.2 g/dL increase (2mg) and 1.9 g/dL increase (5mg) in mean change from baseline in Hb across dosing cohorts at Day 28 in SCD patients[44] - In LR-MDS, 40% of low transfusion burden cohort achieved transfusion independence with tebapivat[51]

A Scaled CRDMO Platform Delivering Sustainable High Growth Use of Adjusted Financial Measures (Non-IFRS Measures) We have provided adjusted net profit, adjusted net profit margin, adjusted gross profit, adjusted gross profit margin, adjusted EBITDA, adjusted EBITDA margin and adjusted basic earnings per share for the corresponding periods, which excludes the share-based compensation expenses, listing expenses, gains or losses from equity investments and foreign exchange gains or losses, and are not required ...

Financial Performance Highlights - The company reported revenues of $85.2 billion, up 6% year-over-year[9], or $86.4 billion excluding notable items, up 7% year-over-year[9] - Net income was $14.3 billion, up 13% year-over-year[9], or $16.1 billion excluding notable items, up 27% year-over-year[9] - Earnings per share (EPS) was $6.99, or $7.97 excluding notable items[9] - The company's Return on Tangible Common Equity (RoTCE) was 7.7%, up 70 bps year-over-year[9], or 8.8% excluding notable items, up 180 bps year-over-year[9] Business Segment Results - Services revenues reached $21.3 billion[11], up 8% year-over-year[32] - Markets revenues totaled $22.0 billion[11], up 11% year-over-year[37] - Banking revenues were $8.2 billion[11], up 32% year-over-year[41] - Wealth revenues amounted to $8.6 billion[11], up 14% year-over-year[46] - U S Personal Banking (USPB) revenues were $21.0 billion[11], up 5% year-over-year[54] Capital and Liquidity - The company's Common Equity Tier 1 (CET1) Capital Ratio was 13.2%, approximately 160 bps above regulatory requirements[9, 27] - The company returned over $17.5 billion to common shareholders, including $13.25 billion in share repurchases[9] Outlook - The company projects Net Interest Income (NII) excluding Markets to grow by 5-6% year-over-year in 2026[67] - The company is targeting an efficiency ratio of approximately 60% and positive operating leverage for 2026[69] - The company is targeting a return of 10-11% in 2026[72]

Company Overview - Treace Medical Concepts is focused on the surgical treatment of bunions and related deformities[7] - The company reported preliminary FY 2025 revenue of $212.3 million to $212.7 million, representing approximately 2% year-over-year growth at the midpoint[7] - Approximately 1/3 of US Foot & Ankle Surgeons used Treace bunion systems in 2025[7] Market Opportunity - Approximately 67 million Americans are affected by bunions[9] - Annually, 4.4 million people seek medical treatment for bunions, with 1.1 million being surgical candidates, representing a $5 billion+ US market opportunity[9] - The current US market for bunion surgical procedures is $2.3 billion, with podiatrists performing 75% of the surgeries and orthopedists performing 25%[9, 11] Technology and Clinical Outcomes - In nearly 90% of bunions, the metatarsal bone is rotated in the frontal plane[15] - Failure to correct the frontal plane component can lead to a 10-12x greater risk of recurrence[18] - Lapiplasty patients experienced early weight bearing at 7.7 days (average) in a walking boot[23] - Lapiplasty patients experienced low recurrence rates of 0.8% (HVA >20°) & 8.4% (HVA >15°) at 48 months[23] - Lapiplasty patients experienced 81% pain reduction with 89% improvement in MOxFQ walking/standing scores at 48 months[23] Future Growth and Strategy - 58% of surgeons expect MIS osteotomies to be their fastest-growing bunion procedure in the next year[35] - 56% of bunion patients would "greatly increase interest" in surgery with an MIS option[36]

EVERY BREAKTHROUGH BEGINS WITH BELIEF 44th Annual J. P. Morgan Healthcare Conference January 2026 Rachel McMinn, Ph.D. Founder and Chief Executive Officer Disclaimer Forward Looking Statements Industry and Market Data Certain information contained in this Presentation relates to or is based on studies, publications, surveys and Neurogene's own internal estimates and research. In this Presentation, Neurogene relies on, and refers to, publicly available information and statistics regarding market participants ...

The New Backbone of Retina Care: Moving Beyond Lifelong Injections Corporate Overview J.P. Morgan Healthcare Conference | January 2026 This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities. © 2026 4D Molecular Therapeutics. All Rights Reserved. 2 Overview 1 4DMT Vision & Pipeline 2 4D-150 Overview & 2025 Accomplishments 3 Retinal Vascular Disease Market & Unmet Medical Needs 4 Derisking Phase 3 & Commercialization 5 2026-27 Catalysts 6 Summary © 2026 4D Mo ...

Turning Strategy into Results Jean-Christophe Tellier, CEO 44th Annual J.P. Morgan Healthcare Conference January 14th, 2026 Disclaimer & Safe Harbor This document contains forward-looking statements, including, without limitation, statements containing the words "potential", "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All sta ...

Financial Performance - Net income for 4Q25 was $5.4 billion, or $1.62 per diluted share, including $612 million in severance expense[5] - Excluding severance expense, net income was $5.8 billion, or $1.76 per diluted share[7] - Revenue reached $21.3 billion, a 4% increase[7] - Noninterest income was $9.0 billion, up 5%[4] - Noninterest expense was $13.7 billion, down 1%[4] - Pre-tax pre-provision profit was $7.6 billion, up 17%[4] Balance Sheet and Capital - Average loans totaled $955.8 billion, up 5%[4] - Average deposits reached $1.4 trillion, up 2%[4] - Common Equity Tier 1 (CET1) capital was $137.3 billion[4] - CET1 ratio stood at 10.6%[4] - Liquidity coverage ratio (LCR) was 119%[4] - Total Loss Absorbing Capacity (TLAC) ratio was 23.2%[4]